 Home > Active Ingredient News > Drugs Articles > Hutchison Medicine will announce the latest clinical data of 3 anticancer drugs at ESMO Annual Meeting

Hutchison Medicine will announce the latest clinical data of 3 anticancer drugs at ESMO Annual Meeting

 Last Update: 2021-09-10
 Source: Internet
 Author: User

Tags

drug injection

intrepid edge label

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 7th, Hutchison Medicine announced that the company will announce the latest and updated versions of a variety of anticancer drugs at the 2021 European Society for Medical Oncology (ESMO) online annual meeting to be held from September 16 to 21, 2021.

Including PI3Kδ inhibitor HMPL-689, MET inhibitor Saivotinib and VEGFR inhibitor Fruquintinib

HMPL-689 (amdizalisib) is a new, selective and potent oral PI3Kδ isomer inhibitor

HMPL-689 (amdizalisib) At this conference, Hutchison Medicine will announce the results of the Phase 1b study of HMPL-689 in the treatment of Chinese patients with relapsed/refractory lymphoma

In addition to the ongoing Phase 2 clinical trials and supporting Phase 1 clinical trials in China, the Phase 1/1b clinical trials of HMPL-689 in the United States and Europe are also underway for the treatment of relapsed or refractory non-Hodgkin's lymph.

Savolitinib is a potent and highly selective oral mesenchymal transition factor (MET) tyrosine kinase inhibitor (TKI).

Savoritinib

Currently, Syvotinib is being used as a single-agent therapy or a combination therapy with other drugs, and is clinically developed for the treatment of multiple tumor types including lung cancer, kidney cancer and gastric cancer

And the male Buao Xi Huang medicine imatinib and who Wolfowitz interim analysis of study results ORCHARD erlotinib combination therapy of advanced progression after first-line treatment of diseases Osh imatinib non-small cell lung cancer patients

Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3

Fruquintinib (fruquintinib) researchers will announce the results of an open-label Phase 1b/2 study designed to evaluate the safety of the combination of fruquintinib and tislelizumab in the treatment of patients with advanced triple-negative breast cancer Sex and efficacy

The annual ESMO conference is coming soon

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options

references:

[1] Hutchison Medicine will announce the latest clinical data at the ESMO online annual meeting in 2021.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.